GeneFrontier Corporation (GFC) is a Japanese biotech company, which is one of the group companies of KANEKA Corporation. GFC is focusing on biopharmaceutical R&D support business with innovative products and services especially in protein based biologics including antibody.
GFC provides powerful tool for synthesizing protein or peptides, which is cell-free protein synthesis system, also known as in vitro protein synthesis. The system called PUREfrex can be provided from small-scale to large-scale reaction volumes such as kits, on demand.
PUREfrex is a reconstituted in vitro coupled Transcription/Translation Systems, completely different from an E.coli extract S30 system. GFC has been improving a protein/peptide productivity with optimizing the composition of all factors for transcription and translation. Supplement is also available for helping folding and forming disulfide bond.
Our aim is to explore the potential of protein based Biologics, and contributes the development of innovative therapeutics.
in vitro Coupled Transcription/Translation
We have been collaborating with MorphoSys AG, and introducing their proprietary technologies to Japanese market.
GeneFrontier has not received any reviews.
GeneFrontier has not received any endorsements.